• News
  • BioTech

La Jolla Pharmaceutical gets investment

La Jolla Pharmaceutical Co. announced a $2.9 million investment by existing preferred shareholders.

The cash will fund a clinical trial to treat patients with chronic kidney disease.

The firm and stockholders entered into a consent and waiver agreement that released $2.9 million of previously restricted cash to the company to fund operations.

The stockholders also waived the right to redeem their preferred stock on Jan. 20, 2013.

GCS-100, the company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer.

"This financing is an important milestone for La Jolla. We thank our investors for their confidence in our team and the program we have planned for GCS-100," said George Tidmarsh, M.D., Ph.D., La Jolla's president and CEO.

Proceeds from the financing will be used for a planned clinical trial of GCS-100 in chronic kidney disease, as well as general corporate expenses.

User Response
0 UserComments

La Jolla Pharmaceutical Co.

Company Website

6455 Nancy Ridge Dr.
San Diego, CA 92121

La Jolla Pharmaceutical Co. Executive(s):

Deirdre Gillespie

  • Chief Executive Officer, President

George Tidmarsh

  • Chief Executive Officer, President

Similar Companies

NAICS - 541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)